Pharmaceuticals (Mar 2022)

Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles

  • Lina Zhou,
  • Sunitha Kodidela,
  • Sandip Godse,
  • Stacey Thomas-Gooch,
  • Asit Kumar,
  • Babatunde Raji,
  • Kaining Zhi,
  • Harry Kochat,
  • Santosh Kumar

DOI
https://doi.org/10.3390/ph15030358
Journal volume & issue
Vol. 15, no. 3
p. 358

Abstract

Read online

The blood brain barrier (BBB) maintains the homeostasis of the central nervous system (CNS) and protects the brain from toxic substances present in the circulating blood. However, the impermeability of the BBB to drugs is a hurdle for CNS drug development, which hinders the distribution of the most therapeutic molecules into the brain. Therefore, scientists have been striving to develop safe and effective technologies to advance drug penetration into the CNS with higher targeting properties and lower off-targeting side effects. This review will discuss the limitation of artificial nanomedicine in CNS drug delivery and the use of natural extracellular vesicles (EVs), as therapeutic vehicles to achieve targeted delivery to the CNS. Information on clinical trials regarding CNS targeted drug delivery using EVs is very limited. Thus, this review will also briefly highlight the recent clinical studies on targeted drug delivery in the peripheral nervous system to shed light on potential strategies for CNS drug delivery. Different technologies engaged in pre- and post-isolation have been implemented to further utilize and optimize the natural property of EVs. EVs from various sources have also been applied in the engineering of EVs for CNS targeted drug delivery in vitro and in vivo. Here, the future feasibility of those studies in clinic will be discussed.

Keywords